Skip to Content

Davide Campari-Milano NV Az nom Post Frazionamento

CPR: XMIL (ITA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
€5.00HhhqwQmyyjbxpj

Campari’s 9M Report Better Than Expected; Near-Term Remains Precarious, and Shares at a Premium

Like other distillers we cover, shares of narrow-moat Campari Group had rallied meaningfully in the last few months, setting up an interesting nine-month earnings release. The results were solid, with sales ahead and profit roughly in line with our expectations. Nevertheless, a plethora of risks remains as COVID-19 lingers across key markets, and the firm remains reliant on an increasingly tenuous on-premises recovery, especially in Italy. We plan to raise our fair value estimate to EUR 7.90 from EUR 7.40 to reflect the time value of money and slightly better profitability this year, but given the lofty current trading levels, the risk/reward proposition remains uncompelling, in our view.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of CPR so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center